Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about European projects that are funded by European programmes including FP7, H2020, IMI, JNPD, AAL and EU Health.

Filters

(Clear all)

A European multicentre double-blind placebo-controlled phase III trial of nilvadIpine in mild to moderate Alzheimer’s disease

NILVAD

Alzheimer’s disease (AD) is an ever-increasing public health concern among the aging population and is the most common form of dementia affecting more than 15 million individuals worldwide and around 5 million Europeans. The direct and indirect costs of AD and other dementias amount to more than €440,000 million each year (www.alz.org, 2010).Even...

Funding Programme
Start Date
End Date
Total Funding
€ 7 916 016

ACces to Timely Formal Care

ACTIFcare

In the absence of a cure for dementia, most research is aimed at an early diagnosis as it opens the way to timely future care and treatment, and can help people take control of their lives and plan ahead. However, people with moderate to severe dementia and their carers are often not receiving services of the type, quality and timing that they need...
Funding Programme
Start Date
End Date
Total Funding
€ 2 396 428
European Countries Involved

ADAMtx: Development of Alzheimer’s immunotherapy by harnessing the natural reparative properties of microglia

ADAMtx

Alzheimer's disease (AD) is a heterogeneous disease in which multiple detrimental factors contribute to cognitive loss and disease escalation. Currently there are no effective therapies for AD. Targeting any single symptom of disease-escalating factor (e.g. amyloid beta, tau, neuroinflammation etc.), even if successful, is not sufficient to modify...
Funding Programme
Start Date
End Date
Total Funding
€ 150 000
European Countries Involved

Biological Resource Analysis to Identify New Mechanisms and phenotypes in Neurodegenerative Diseases

BRAIN-MEND

Neurodegenerative diseases include Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, frontotemporal dementia, corticobasal degeneration, multiple system atrophy and progressive supranuclear palsy. We currently classify and treat these conditions based on symptoms and clinical findings. Although this approach seems logical, it...
Funding Programme
Start Date
End Date
Total Funding
€ 2 100 000
European Countries Involved

Biomarker based diagnosis of rapid progressive dementias – optimisation of diagnostic protocols.

DEMTEST

DEMTEST has established a large European and global collaboration between national surveillance units and dementia research centres, facilitating cooperation between neurologists, neuropathologists and neuroscientists. We work on standardisation of tests that are currently available and harmonise their use between centers worldwide. We define...
Funding Programme
Start Date
End Date
Total Funding
€ 2 200 000

Biomarkers for Alzheimer’s disease and Parkinson’s disease.

BIOMARKAPD

Neurodegenerative disorders, represented mostly by Alzheimer's disease (AD) and Parkinson's disease (PD), are characterised by progressive neuronal impairment and death. In spite of the brain's known capacity for regeneration, lost neurons generally cannot be replaced. Therefore, drugs aimed at inhibiting neurodegenerative processes are likely to...

Funding Programme
Start Date
End Date
Total Funding
€ 449 066

CARELINK for People with Dementia and their community

CARE-LINK

The objective of CARELINK is to deliver a tracking solution that addresses the issue of wandering in People with Dementia (PwD), allowing carers to monitor PwD. Using current machine-learning technologies we will profile user routes that can then be used to build a repository of route patterns to be compared against live routes, thus allowing for...

Funding Programme
Start Date
End Date
Total Funding
€ 2 282 944
European Countries Involved

Coordination Action in support of the implementation of a Joint Programming Initiative for Combating Neurodegenerative Diseases, in particular Alzheimer’s disease

JUMPAHEAD

The objective of the Coordination Action JUMPAHEAD is to support the implementation of the pilot Joint Programming Initiative on combating neurodegenerative diseases, in particular Alzheimer’s disease (JPND). Neurodegenerative disorders are incurable and debilitating conditions that result in progressive degeneration or death of nerve cells. Of...
Funding Programme
Start Date
End Date
Total Funding
€ 2 618 090

Dementia Ambient Care: Multi-Sensing Monitoring for Intelligent Remote Management and Decision Support

Dem@Care

The increase in average lifespan across the world has been accompanied by an unprecedented upsurge in the occurrence of dementia with high socio-economic costs. The development of personal health systems provides a means of dealing with such problems in a meaningful and sustainable manner, enabling persons with dementia to maintain independence and...
Funding Programme
Start Date
End Date
Total Funding
€ 10 626 393
European Countries Involved

Dementia: Intersectorial Strategy for Training and Innovation Network for Current Technology (DISTINCT)

DISTINCT

The main aim of DISTINCT will develop a premier quality multi-disciplinary, multi-professional and intersectorial education and training research framework for Europe aimed at improving technology and care for people with dementia and their carers, and to use coherent themes an.d interrelated ESRs within DISTINCT to provide the evidence to show how...
Funding Programme
Start Date
End Date
Total Funding
€ 3 998 048
European Countries Involved

Do nanoparticles induce neurodegenerative diseases? Understanding the origin of reactive oxidative species and protein aggregation and mis-folding phenomena in the presence of nanoparticles

NEURONANO

As the use of nanoparticles becomes more prevalent, it is clear that human exposure will inevitably increase. Considering the rapidly ageing European population and the resulting increase in the incidence of neurodegenerative diseases, there is an urgent need to address the risk presented by nanoparticles towards neurodegenerative diseases. It is...

Funding Programme
Start Date
End Date
Total Funding
€ 4 823 050
European Countries Involved

European Patient Organizations in Knowledge Society

EPOKS

The last two decades have witnessed the increasing role of patient, user and civil society organizations (POs and CSOs) in the production of knowledge on diseases and health problems. Rich and detailed studies have shown that this phenomenon entails new forms of activism. It also questions the modes of governance of knowledge, as well as the role...
Funding Programme
Start Date
End Date
Total Funding
€ 1 129 013
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).